What you need to know about ZMapp

Q: What is ZMapp?

A: It is a cocktail of specially engineered antibodies designed to target and inactivate the Ebola virus.

Q: What do we know about whether it works?

A: Very little. Various antibodies have been tested in small numbers of monkeys but not people. In one study, 43 percent of treated monkeys survived when the drug was given after the animals showed symptoms.

Q: Why isn't ZMapp being tested more widely to find out if it works in people?

A: There's not enough available. The antibodies are grown inside tobacco plants and then extracted and purified, a slow process. US officials have estimated that only a modest amount could be produced in two or three months, unless some way to speed production is found.

Q: What does it mean that the two American aid workers who received the drug are reported to be slowly improving?

A: Top US health officials stress that there's no way to know if the drug really helped, or if those two patients would have been among the 40 percent of people who are surviving this outbreak anyway. Without human studies, there also isn't any way to know if the drug might harm instead of help.

Q: How were the Americans and Spanish priest chosen to get some of those limited doses, rather than Africans?

A: The international relief organisation Samaritan's Purse and Emory University Hospital requested that the manufacturer provide some of the drug for the two Americans, and the manufacturer agreed. As for the Spanish missionary priest, it wasn't clear exactly how Spanish officials obtained a dose that apparently was in Geneva. The priest also was infected in Liberia and is in isolation at a Madrid hospital.

Q: How is Liberia getting the drug?

A: The U.S. Department of Health and Human Services said it had helped connect Liberia with the manufacturer. “Since the drug was shipped for use outside the US, appropriate export procedures had to be followed,” the statement said.

Q: Are any other drugs in the pipeline?

A: Canada's Tekmira Pharmaceuticals Corp is developing a drug that targets Ebola's genetic material. The FDA had halted a small safety study with questions about a reaction in healthy volunteers. Last week, Tekmira announced that FDA had modified its restriction, clearing a roadblock to possible experimental use in infected patients. The company said at the time that it was “carefully evaluating options.”

A handful of other companies are in earlier stages of drug development and a possible vaccine to prevent the disease is expected to begin first-stage safety studies sometime in the autumn.

Q: If experimental drugs won't stop the outbreak, what will?

A: Experts say old-fashioned public health measures: rapidly finding and isolating the sick, quarantining those exposed and educating the public on how to avoid the risk of infection. Ebola is spread through direct contact with bodily fluids of sick patients. Two main drivers of the outbreak are thought to be improper infection control during patient care and traditional but risky burial practices that see mourners handling bodies that are still infectious.